Physician
Manuel Demirovic
Department of Neurology, Odense University Hospital
| Project management | ||
| Project status | Open | |
| Data collection dates | ||
| Start | 01.03.2025 | |
| End | 31.10.2026 | |
The multicentre DREAMS study: Danish real-world evaluation of subcutaneous ocrelizumab and patient satisfaction
Short summary
Although satisfaction and adherence data about subcutaneous adminstration are available from other study (OCARINA), no real-world study examined such outcomes. Therefore we plan the study to examine treatment satisfaction, adherence, healthcare utilization, adverse events and disease activity on subcutaneous administration compared to iv. administration.
Rationale
Our hypothesis: Patients who switch from IV to SC Ovrelizumab express high satisfaction at switch and during the study duration.
Description of the cohort
We aim to include 100 patients, who are diagnosed with Multiple Sclerosis and are under ocrelizumab treatment.
Data and biological material
questionnaires, physical examination and data from patient journal